According to a randomized clinical trial, patients with recurrent or refractory anaplastic astrocytoma lived almost twice as long when treated with an investigational targeted agent than with standard therapy.

According to a randomized clinical trial, patients with recurrent or refractory anaplastic astrocytoma lived almost twice as long when treated with an investigational targeted agent than with standard therapy. Read the full article >